J.P. Morgan Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

J.P. Morgan analyst maintained a Buy rating on Jazz Pharmaceuticals today and set a price target of $265.00.

Meet Samuel – Your Personal Investing Prophet

• Start a conversation with TipRanks’ trusted, data-backed investment intelligence
• Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

In addition to J.P. Morgan, Jazz Pharmaceuticals also received a Buy from UBS’s Ashwani Verma in a report issued yesterday. However, on May 5, UBS reiterated a Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ).

Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.07 billion and a net profit of $293.1 million. In comparison, last year the company earned a revenue of $897.84 million and had a GAAP net loss of $92.54 million

Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Most recently, in March 2026, Patricia Carr, the SVP & CAO of JAZZ sold 2,723.00 shares for a total of $503,645.50.